Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study

M M Shinohara; H M Mahurin; E Tarabadkar; D S Hippe; K Lachance; E J Kim; E T Loggers

doi:10.1002/ski2.45

Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study

Skin Health Dis. 2021 May 15;1(3):e45. doi: 10.1002/ski2.45. eCollection 2021 Sep.

Authors

M M Shinohara¹, H M Mahurin², E Tarabadkar³, D S Hippe⁴, K Lachance¹, E J Kim⁵, E T Loggers^{6

7}

Affiliations

¹ Division of Dermatology University of Washington Seattle Washington USA.
² School of Medicine University of Washington Seattle Washington USA.
³ Department of Dermatology Emory University Atlanta Georgia USA.
⁴ Department of Radiology University of Washington Seattle Washington USA.
⁵ Department of Dermatology University of Pennsylvania Philadelphia Pennsylvania USA.
⁶ Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington USA.
⁷ Division of Hematology/Oncology Department of Medicine University of Washington Seattle Washington USA.

PMID: 35663135
PMCID: PMC9060149
DOI: 10.1002/ski2.45

Abstract

Background: Patients with cutaneous T-cell lymphoma (CTCL) often have indolent but symptomatic disease.

Objective: Assessment of the health-related quality of life (HRQoL) of patients with CTCL.

Methods: Cross-sectional survey study. HRQoL was measured by Skindex-16 and FACT-G.

Results: A total of 372 responses were received; 80 incomplete/ineligible responses were excluded. A majority of respondents identified as white (87%; 250/288) and female (67%; 193/286) with a mean age of 57 ± 14 years. Most patients had early-stage (IA-IIA) (74%; 162/203) mycosis fungoides (87%; 241/279). There were 33 (12%; 33/279) patients with Sézary syndrome. Mean itch score (visual analogue scale; VAS) was 3.2 ± 2.8, overall; 2.7 ± 2.6 for early, and 4.2 ± 2.9 for advanced disease (p = 0.008). Thirty-eight percent (108/284) and 24% (69/284) reported head/neck and groin/genital involvement, respectively.Overall HRQoL was 46 ± 27 (Skindex-16) and 71 ± 19 (FACT-G), with worse HRQoL for patients with advanced versus early disease (Skindex-16: 67 vs. 40; p=<0.001, FACT-G: 62 vs. 76; p = 0.001). Predictors of worse HRQoL included head/neck, hand/foot or groin/genital involvement, younger age and spending >15 min daily treating CTCL.

Limitations: Include anonymous survey methodology, underrepresentation of certain CTCL subtypes and non-white respondents.

Conclusions: Patients with CTCL, particularly those with advanced disease or involvement of the head/neck, acral or groin/genital sites, experience significant impact on HRQoL.